Trials / Completed
CompletedNCT01015027
Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study of the Safety and Tolerability of Intravenously Administered REGN668 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will test the safety and tolerability (how the body reacts to the drug) of REGN668 and placebo (an inactive substance that contains no medicine) in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | REGN668 | 4 IV Cohorts (Dose 1, 2, 3, \& 4) |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2009-11-17
- Last updated
- 2013-06-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01015027. Inclusion in this directory is not an endorsement.